The verdict
Our read at a glance.
Whether an approved indication in serious anaemia makes the hepatic risk profile acceptable outside that indication.
- The signal
- The approved use is real: oxymetholone is indicated for anaemias caused by deficient red cell production, including acquired and congenital aplastic anaemia and myelofibrosis, and it has been studied in HIV wasting and in haematological settings where stimulating erythropoiesis and lean mass is the objective. Registered trials continue in defined haematological contexts. In those patients the risk calculus is different because the alternative is a serious untreated disease.
- The unknown
- Nothing about the efficacy is mysterious. The unresolved question is entirely about cumulative hepatic risk in healthy users, where exposure is unmonitored and no imaging or enzyme surveillance is happening.
- Our read
- The drug where the label does the arguing. Approved, effective, and carrying warnings about liver cysts that can rupture and tumours that are often silent until they are not. Used medically, that trade buys treatment for a serious anaemia. Used for a peak week, it buys a photograph.
The mechanism
How it works.
Oxymetholone is a 17-alpha-alkylated dihydrotestosterone derivative with a 2-hydroxymethylene group. The 17-alpha methylation makes it orally active and is responsible for the hepatic liability. Its erythropoietic effect - the reason it is an approved anaemia drug - comes from androgen-driven stimulation of erythropoietin production and of the bone marrow's response to it, which raises red cell mass. That same effect raises haematocrit in healthy users, which is a thrombotic risk rather than a benefit. Although it derives from dihydrotestosterone and is not a classical aromatase substrate, it has direct oestrogenic activity at the oestrogen receptor, which is why it produces oestrogen-like effects that aromatase inhibitors do not resolve.
Safety & regulatory boundary
The consequential part.
Approved only for specific anaemias and a Schedule III controlled substance. Its labelling carries explicit warnings about peliosis hepatis - blood-filled cysts in the liver that can rupture - hepatic tumours, and blood lipid changes, with the observation that these conditions are often not recognised until life-threatening. It is 17-alpha-alkylated, strongly aromatising in practice, sharply suppressive of HDL, and markedly water-retaining. Prohibited in sport.
What's next
What we're watching.
Continued haematology trials, and any case surveillance of hepatic outcomes in non-medical users.
Context
Why this is discussed.
It produces faster visible size and strength gain than almost anything else, which is exactly why it is used in the run-up to competition.
The evidence base
16 cited references.
Registered trials4
ClinicalTrials.gov · NA · RECRUITING · 2025-02-12
ClinicalTrials.gov · NA · COMPLETED · 2023-10-26
ClinicalTrials.gov · PHASE2 · COMPLETED · 2015-09
ClinicalTrials.gov · PHASE1/PHASE2 · TERMINATED · 2009-11
Indexed literature (PubMed)12
Rep Carcinog · Rep Carcinog · 2004
Bowers M · BETA · 1998
National Toxicology Program · Rep Carcinog · 2011
National Toxicology Program · Rep Carcinog · 2002
Pavlatos AM et al. · Clin Ther · 2001
Kratena N et al. · Steroids · 2019
Saba AI et al. · Diseases · 2023
McCredie KB · Br J Haematol · 1969
Wood P et al. · Clin Lab Haematol · 1994
Chaipokam J et al. · Ann Hematol · 2025
Alexanian R et al. · Blood · 1975
Brickman CM et al. · Int J Dermatol · 1983
Keep reading